

CSL Behring

Biotherapies for Life™



Driven by **Our Promise™**

Driven by Our Promise™

At CSL Behring, our deep commitment to delivering on our promise to patients is what unites us in doing our work, every day.

There are more than 25,000 employees of the CSL Group, which includes CSL Behring and Seqirus, one of the world's leading influenza vaccine providers. We are dedicated to discovering, developing and delivering innovative medicines. Our work helps save lives and protect public health in over 100 countries.

From our founding more than a century ago, we have operated with scientific excellence at the heart of everything we do.

That core principle, together with our foundational Values, guides us as we move into new therapeutic areas and treatments on the leading edge of medicine.

Today, our future has never looked brighter.

OUR VALUES

Patient Focus

We deliver on our promise to patients.

Innovation

We turn innovative thinking into solutions.

Integrity

We walk the talk.


Collaboration

We are stronger together.

Superior Performance

We take pride in our results.

Worldwide locations of CSL, including CSL Behring and Seqirus





“Throughout CSL, we remain committed to fostering a culture in which our people feel both inspired and encouraged to come to work so patients will benefit.”

Paul Perreault
Chief Executive Officer & Managing Director
CSL Limited

Driven by Our Patients

Millions of people around the world are living with rare and serious medical conditions. CSL Behring is committed to delivering medicines that improve their lives.

Patients aren't simply the people we serve: they are a crucial part of the process of creating our lifesaving therapies. The input we seek and receive from patients helps us identify their unmet needs and collaborate to develop products that fulfill them. Beyond making medicine, we work closely with patient organizations on issues of advocacy, awareness

and access. We also provide support to individual patients and their families through innovative programs that facilitate connections through peer mentoring and social activities.

Patients are the reason CSL Behring exists, and our promise to them has never been stronger.



ON THE COVER

Cheryl French and her daughters, Leah (center) and Emma, are living with hereditary angioedema (HAE), a rare disease that can cause swelling in different parts of the body that is painful, debilitating and potentially fatal. HAE is an inherited rare disease that is passed down through generations. Yet Cheryl, Leah and Emma are able to live full lives by managing their condition with the help of therapies developed through years of research into solving patient needs. In the following pages, join the French family in learning about how these lifesaving therapies are developed and delivered for patients around the world.

**MEET KATHRIN SCHOEN,
GERMANY**

She is working to make sure other people with hereditary angioedema (HAE) don't have to wait as long as she did for a diagnosis.

“I want to increase awareness about HAE so that fellow patients are diagnosed sooner and are able to live full, active lives like I do.”



Driven by Our People



Our team of talented colleagues around the globe gives us a competitive advantage and fuels our success as a global biotechnology leader.

We are a purpose-driven company with a values-based culture. Each day, CSL Behring employees work together to tackle some of the world's most complex health problems and to develop breakthrough solutions that save lives. They do so while living our CSL Values.

We are committed to creating a diverse and inclusive workplace environment, an environment where colleagues can fulfill their career aspirations, realize their potential, and leverage their unique perspectives and experiences to make a difference in a world that needs innovative solutions to rare and serious diseases.



UNIVERSUM

Most Attractive Employer in
Switzerland | 2019, 2020



FORBES

Forbes' Best Employers
for Diversity | 2019, 2020



NIKKEI

Best Company for Corporate
Sustainability | 2019

COME WORK WITH US

See our available positions and explore a promising future at [CSLBehring.com/careers](https://www CSLBehring.com/careers).



We can't think of a better way of driving innovation for patients and public health than by building teams throughout our organization that bring diverse perspectives and ideas to the table.

Elizabeth Walker
Chief Human Resources Officer


Driven by Our Innovation

For more than a century, CSL Behring has linked its strong foundation of science to discovering, developing and delivering novel medicines for unmet patient needs.

Today, CSL Behring has established itself as the industry-leading plasma-based biotech company – progressing into multiple new disease areas across its five therapeutic areas and three scientific platforms. We're also making important investments in our global R&D hubs, expanding our capabilities, and building strategic collaborations with academic institutions,

industry and researchers to help unlock additional sources of innovation.

With an integrated and broad pipeline of therapies, diverse sources of innovation and a science- and business-driven approach – the company is well positioned to deliver innovative medicines for patients with rare or serious diseases in the decades ahead.



OUR R&D SITES

- Bern, Switzerland
- Kankakee, Illinois
- King of Prussia, Pennsylvania
- Marburg, Germany
- Melbourne, Australia
- Pasadena, California
- Sydney, Australia
- Tokyo, Japan
- Wuhan, China

1,700⁺ R&D employees



US \$ **4.1 billion**
in R&D investments in the last 5
years to advance product pipeline

**SEE WHAT WE'RE
WORKING ON**

Go to [CSLBehring.com/r-and-d](https://www.CSLBehring.com/r-and-d)
to see our product pipeline.



CSL Behring aims to continually deliver on our promise to create a future for our patients and our company that has never looked brighter.

Bill Mezzanotte, M.D., MPH
Executive Vice President, Head of R&D and Chief Medical Officer

Driven by Our Efficiency



Dedication to operational excellence is a key component of our power to deliver our medicines to our millions of patients worldwide.

Our restructured end-to-end operations organization and strategy are enhancing our ability to meet growing demand and bring more therapies to more patients.

CSL Behring's manufacturing hubs are located on four continents and are powered by our subsidiary CSL Plasma, one of the world's largest plasma collection networks. We are cultivating a global, enterprise-level mindset that ensures quality and safety throughout the entire product lifecycle, from donor to patient.

An agile and responsive supply chain is a key reason why our patients look to us as a reliable partner in their care.


Fueled by **PLASMA**
300+ **COLLECTION**
CENTERS



5 manufacturing
sites on
4 continents

INVESTMENT IN INFRASTRUCTURE

By continually investing in our manufacturing sites and driving efficiency, we are well-positioned to meet global demand for our products.



We are building on our existing strengths to create best-in-class, scalable processes that efficiently deliver top-tier results for safety, quality, reliability and innovation.



Paul McKenzie
Chief Operating Officer

Driven by Our Communities

Strong relationships with communities – especially healthcare providers, patient support communities and areas in which we operate – are critical to delivering on our promise. These relationships keep us connected to the evolving needs of patients and other stakeholders, so we can better support them.


Our community initiatives include:

1 Drawing on our heritage as a leader in public health to immediately launch numerous scientific initiatives to address the COVID-19 pandemic, including partnering with other industry leaders and our colleagues in academia.

2 Partnering with six National Urban League affiliates around the U.S. to address some of the most pressing needs in the communities in which we live and work.

3 Launching the CSL Behring Research Acceleration Initiative, which funds promising research among academia to bring innovation from the laboratory to patients.

Collaborative relationships with communities are an important part of our commitment to advance scientific knowledge and foster the next generation of medical researchers, as well as enhance the quality of life for patients and improve access to our medicines.



US \$

55.2 million

in Community Contributions




1

GIVING BACK GLOBALLY

1

COVID-19
response



2

2

National
Urban League
partnership

3

CSL Behring labs
at Philadelphia's
University City
Science Center,
a key partner in
our Research
Acceleration
Initiative



3

Driven by Our Principles

CSL Behring is an award-winning company whose work is recognized around the world.

LEADERSHIP

CEO & Managing Director
Paul Perreault

The CEO 100
Harvard Business Review, 2019

Business Person of the Year
Australian Financial Review, 2019

CEO of the Year
Business Daily, Australia, 2019

Most Admired CEO
Philadelphia Business Journal, 2018

WORKPLACE

Best Employers for Diversity in U.S.
Ranked in 2019 and 2020 by Forbes

**Top 100 Companies in
Global Diversity and Inclusion**
Ranked in 2018 by Thomson Reuters

Top 50 Employers in the World
Ranked in 2017 and 2018 by Forbes

Read thoughtful and compelling stories, insights from industry experts, and information about biotech's promise on our award-winning digital news channel, Vita. Go to [CSLBehring.com/Vita](https://www.CSLBehring.com/Vita) to learn more.

Visit [CSLBehring.com](https://www.CSLBehring.com) to learn more about us and our place as a biotechnology leader.



CSL Behring

Biotherapies for Life™

© September 2021 CSL Behring LLC.

1020 First Avenue | PO Box 61501 | King of Prussia, PA 19406-0901 | [CSLBehring.com](https://www.CSLBehring.com)
[CSLBehring.com/Vita](https://www.CSLBehring.com/Vita) | [Twitter.com/CSLBehring](https://twitter.com/CSLBehring) | [Linkedin.com/company/csl-behring/](https://www.linkedin.com/company/csl-behring/)